Skip to main content
Log in

Radiologische Bildgebung beim CUP-Syndrom

Radiological imaging in CUP syndrome

  • Leitthema: CUP
  • Published:
Die Radiologie Aims and scope Submit manuscript

Zusammenfassung

Problem

Wenn bei metastasierten Tumorerkrankungen kein offensichtlicher Primärtumor nachweisbar ist („cancer of unknown primary“, CUP), sollte dieser dennoch möglichst identifiziert werden, da eine spezifische Therapie bessere Resultate erzielt als eine empirische, palliative Behandlung.

Methodik

Die neue Leitlinie der European Society of Medical Oncology (ESMO) definiert Algorithmen zur Abklärung bei CUP-Syndrom, bei denen radiologische und nuklearmedizinische Bildgebungsverfahren eine zentrale Stellung einnehmen. Wichtige Hinweise auf einen möglichen Primärtumor sind Größe und Morphologie von Herden und das Vorliegen einer dominanten Läsion, ebenso das Muster von hämatogen metastatisch befallenen Organen sowie die anatomische Verteilung befallener Lymphknoten.

Schlussfolgerung

Bei Patienten mit Metastasen spielt beim Auffinden eines möglichen Primärtumors die bildgebende Diagnostik eine wichtige Rolle, aber die Befunde müssen in Kenntnis der klinischen und immunhistochemischen Befunde erhoben werden. In schwierigen Fällen sollte interdisziplinär zwischen Referenzonkologie, -radiologie und -pathologie über das Vorliegen eines CUP-Syndroms beraten werden.

Abstract

Problem

If no obvious primary tumour is detectable in metastatic tumours (cancer of unknown primary, CUP), it should nevertheless be identified if possible, as specific therapy achieves better results than empirical, palliative treatment of CUP.

Methodology

The new guideline of the European Society of Medical Oncology (ESMO) defines algorithms for the evaluation of CUP, in which radiological and nuclear imaging procedures play a central role. Important clues to a possible primary tumour are the size and morphology of foci and the presence of a dominant lesion, as well as the pattern of hematogeneous metastatic spread in affected organs, and the anatomical distribution of affected lymph nodes.

Conclusion

In patients with metastases, imaging plays an important role in identifying a possible primary tumour, but the diagnosis must be made with knowledge of the clinical and immunohistochemical results. In difficult cases, there should be interdisciplinary consultation between reference oncology, radiology, and pathology on the presence of CUP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Golfinopoulos V, Pentheroudakis G, Kamakari S, Metaxa-Mariatou V, Pavlidis N (2009) Donor-derived breast cancer in a bone marrow transplantation recipient. Breast Cancer Res Treat 113:211–213

    Article  PubMed  Google Scholar 

  2. Krämer A et al (2022) Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. https://doi.org/10.1016/j.annonc.2022.11.013

    Article  PubMed  Google Scholar 

  3. Hemminki K, Sundquist K, Sundquist J, Ji J (2015) Risk of cancer of unknown primary after hospitalization for autoimmune diseases. Int J Cancer 137:2885–2895

    Article  CAS  PubMed  Google Scholar 

  4. Hemminki K, Försti A, Sundquist K, Li X (2016) Cancer of unknown primary is associated with diabetes. Eur J Cancer Prev 25:246–251

    Article  CAS  PubMed  Google Scholar 

  5. Rassy E, Kattan J, Pavlidis N (2019) Familial cancer of unknown primary. Int J Clin Oncol 24:1328–1331

    Article  PubMed  Google Scholar 

  6. Pentheroudakis G, Golfinopoulos V, Pavlidis N (2007) Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 43:2026–2036

    Article  PubMed  Google Scholar 

  7. Rassy E, Pavlidis N (2019) The currently declining incidence of cancer of unknown primary. Cancer Epidemiol 61:139–141

    Article  PubMed  Google Scholar 

  8. Riihimäki M, Thomsen H, Hemminki A, Sundquist K, Hemminki K (2013) Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer 13:36

    Article  PubMed  PubMed Central  Google Scholar 

  9. Hainsworth JD, Fizazi K (2009) Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol 36:44–51

    Article  CAS  PubMed  Google Scholar 

  10. Hemminki K, Bevier M, Hemminki A, Sundquist J (2012) Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol 23:1854–1863

    Article  CAS  PubMed  Google Scholar 

  11. Culine S et al (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20:4679–4683

    Article  PubMed  Google Scholar 

  12. van der Strate I et al (2023) International consensus on the initial diagnostic workup of cancer of unknown primary. Crit Rev Oncol Hematol 181:103868

    Article  PubMed  Google Scholar 

  13. Kwee TC, Kwee RM (2009) Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 19:731–744

    Article  PubMed  Google Scholar 

  14. Noh S, Shim H (2012) Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas. Cancer Treat Res 76:51–55

    Google Scholar 

  15. Pouyiourou M et al (2021) Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. Eur J Cancer 157:179–189

    Article  PubMed  Google Scholar 

  16. de Bresser J, de Vos B, van der Ent F, Hulsewé K (2010) Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol 36:114–119

    Article  PubMed  Google Scholar 

  17. Gennari A et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32:1475–1495

    Article  CAS  PubMed  Google Scholar 

  18. Kim H et al (2021) Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter data. Radiat Oncol J 39:107–112

    Article  PubMed  PubMed Central  Google Scholar 

  19. Colombo N et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. https://doi.org/10.1136/ijgc-2019-000308

    Article  PubMed  Google Scholar 

  20. Ray-Coquard I et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381:2416–2428

    Article  CAS  PubMed  Google Scholar 

  21. Machiels J‑P et al (2020) Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1462–1475

    Article  PubMed  Google Scholar 

  22. Maghami E et al (2020) Diagnosis and management of squamous cell carcinoma of unknown primary in the head and neck: ASCO guideline. J Clin Oncol 38:2570–2596

    Article  PubMed  Google Scholar 

  23. Parker C et al (2020) Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1119–1134

    Article  CAS  PubMed  Google Scholar 

  24. Hainsworth JD, Schnabel CA, Erlander MG, Haines DW, Greco FA (2012) A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 11:112–118

    Article  PubMed  Google Scholar 

  25. Overby A, Duval L, Ladekarl M, Laursen BE, Donskov F (2019) Carcinoma of unknown primary site (CUP) with metastatic renal-cell carcinoma (mRCC) histologic and immunohistochemical characteristics (CUP-mRCC): results from consecutive patients treated with targeted therapy and review of literature. Clin Genitourin Cancer 17:e32–e37

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Felix T. Kurz.

Ethics declarations

Interessenkonflikt

F.T. Kurz und S. Delorme geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kurz, F.T., Delorme, S. Radiologische Bildgebung beim CUP-Syndrom. Radiologie 63, 346–353 (2023). https://doi.org/10.1007/s00117-023-01145-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00117-023-01145-4

Schlüsselwörter

Keywords

Navigation